Literature DB >> 10049273

8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization.

J L Vennerstrom1, E O Nuzum, R E Miller, A Dorn, L Gerena, P A Dande, W Y Ellis, R G Ridley, W K Milhous.   

Abstract

From the Walter Reed Army Institute of Research (WRAIR) inventory, thirteen 8-aminoquinoline analogs of primaquine were selected for screening against a panel of seven Plasmodium falciparum clones and isolates. Six of the 13 8-aminoquinolines had average 50% inhibitory concentrations between 50 and 100 nM against these P. falciparum clones and were thus an order of magnitude more potent than primaquine. However, excluding chloroquine-resistant clones and isolates, these 8-aminoquinolines were all an order of magnitude less potent than chloroquine. None of the 8-aminoquinolines was cross resistant with either chloroquine or mefloquine. In contrast to the inactive primaquine prototype, 8 of the 13 8-aminoquinolines inhibited hematin polymerization more efficiently than did chloroquine. Although alkoxy or aryloxy substituents at position 5 uniquely endowed these 13 8-aminoquinolines with impressive schizontocidal activity, the structural specificity of inhibition of both parasite growth and hematin polymerization was low.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10049273      PMCID: PMC89166     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  In vitro and in vivo reversal of chloroquine resistance in Plasmodium falciparum with promethazine.

Authors:  A M Oduola; A Sowunmi; W K Milhous; T G Brewer; D E Kyle; L Gerena; R N Rossan; L A Salako; B G Schuster
Journal:  Am J Trop Med Hyg       Date:  1998-05       Impact factor: 2.345

Review 2.  Recent developments in 8-aminoquinoline antimalarials.

Authors:  B K Bhat; M Seth; A P Bhaduri
Journal:  Prog Drug Res       Date:  1984

3.  Activity of quinoline-containing antimalarials against chloroquine-sensitive and -resistant strains of Plasmodium falciparum in vitro.

Authors:  T G Geary; A A Divo; J B Jensen
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

4.  Methemoglobin formation resulting from administration of candidate 8-aminoquinoline antiparasitic drugs in the dog.

Authors:  J C Anders; H Chung; A D Theoharides
Journal:  Fundam Appl Toxicol       Date:  1988-02

5.  Hydroxyl radical formation as a result of the interaction between primaquine and reduced pyridine nucleotides. Catalysis by hemoglobin and microsomes.

Authors:  O Augusto; C L Weingrill; S Schreier; H Amemiya
Journal:  Arch Biochem Biophys       Date:  1986-01       Impact factor: 4.013

6.  In vitro activities of and mechanisms of resistance to antifol antimalarial drugs.

Authors:  W K Milhous; N F Weatherly; J H Bowdre; R E Desjardins
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

7.  Uptake of [3H]chloroquine by drug-sensitive and -resistant strains of the human malaria parasite Plasmodium falciparum.

Authors:  T G Geary; J B Jensen; H Ginsburg
Journal:  Biochem Pharmacol       Date:  1986-11-01       Impact factor: 5.858

8.  In vitro metabolism of the antimalarial agent primaquine by mouse liver enzymes and identification of a methemoglobin-forming metabolite.

Authors:  A Strother; R Allahyari; J Buchholz; I M Fraser; B E Tilton
Journal:  Drug Metab Dispos       Date:  1984 Jan-Feb       Impact factor: 3.922

9.  Oxidative activity of hydroxylated primaquine analogs. Non-toxicity to glucose-6-phosphate dehydrogenase-deficient human red blood cells in vitro.

Authors:  J K Baird; D E Davidson; J E Decker-Jackson
Journal:  Biochem Pharmacol       Date:  1986-04-01       Impact factor: 5.858

10.  The chemotherapy of rodent malaria, XXXVIII. Studies on the activity of three new antimalarials (WR 194,965, WR 228,258 and WR 225,448) against rodent and human malaria parasites (Plasmodium berghei and P. falciparum).

Authors:  W Peters; S G Irare; D S Ellis; D C Warhurst; B L Robinson
Journal:  Ann Trop Med Parasitol       Date:  1984-12
View more
  25 in total

1.  Growth-inhibitory effects of artesunate, pyrimethamine, and pamaquine against Babesia equi and Babesia caballi in in vitro cultures.

Authors:  Akiko Nagai; Naoaki Yokoyama; Tomohide Matsuo; Sabine Bork; Haruyuki Hirata; Xuenan Xuan; Yinchang Zhu; Florencia G Claveria; Kozo Fujisaki; Ikuo Igarashi
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

2.  In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti.

Authors:  Bruno Pradines; Modeste Mabika Mamfoumbi; Adama Tall; Cheikh Sokhna; Jean-Louis Koeck; Thierry Fusai; Joel Mosnier; Eric Czarnecki; André Spiegel; Jean-François Trape; Maryvonne Kombila; Christophe Rogier
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Trioxaquines and heme-artemisinin adducts inhibit the in vitro formation of hemozoin better than chloroquine.

Authors:  Christophe Loup; Joël Lelièvre; Françoise Benoit-Vical; Bernard Meunier
Journal:  Antimicrob Agents Chemother       Date:  2007-08-13       Impact factor: 5.191

4.  Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.

Authors:  Ina L Lauinger; Livia Vivas; Remo Perozzo; Christopher Stairiker; Alice Tarun; Mire Zloh; Xujie Zhang; Hua Xu; Peter J Tonge; Scott G Franzblau; Duc-Hung Pham; Camila V Esguerra; Alexander D Crawford; Louis Maes; Deniz Tasdemir
Journal:  J Nat Prod       Date:  2013-06-19       Impact factor: 4.050

5.  Antimalarial activity of the anticancer histone deacetylase inhibitor SB939.

Authors:  Subathdrage D M Sumanadasa; Christopher D Goodman; Andrew J Lucke; Tina Skinner-Adams; Ishani Sahama; Ashraful Haque; Tram Anh Do; Geoffrey I McFadden; David P Fairlie; Katherine T Andrews
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

6.  Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.

Authors:  Ann K Miller; Emma Harrell; Li Ye; Sharon Baptiste-Brown; Jőrg-Peter Kleim; Colin Ohrt; Stephan Duparc; Jörg J Möhrle; Alison Webster; Sandra Stinnett; Arlene Hughes; Sandy Griffith; Andrew P Beelen
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

7.  Novel type II fatty acid biosynthesis (FAS II) inhibitors as multistage antimalarial agents.

Authors:  Florian C Schrader; Serghei Glinca; Julia M Sattler; Hans-Martin Dahse; Gustavo A Afanador; Sean T Prigge; Michael Lanzer; Ann-Kristin Mueller; Gerhard Klebe; Martin Schlitzer
Journal:  ChemMedChem       Date:  2013-01-22       Impact factor: 3.466

Review 8.  Tafenoquine: First Global Approval.

Authors:  James E Frampton
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

9.  5-Phenoxy Primaquine Analogs and the Tetraoxane Hybrid as Antimalarial Agents.

Authors:  Somruedee Jansongsaeng; Nitipol Srimongkolpithak; Jutharat Pengon; Sumalee Kamchonwongpaisan; Tanatorn Khotavivattana
Journal:  Molecules       Date:  2021-06-30       Impact factor: 4.411

Review 10.  The global pipeline of new medicines for the control and elimination of malaria.

Authors:  Melinda P Anthony; Jeremy N Burrows; Stephan Duparc; Joerg J Moehrle; Timothy N C Wells
Journal:  Malar J       Date:  2012-09-07       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.